Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription 15.07.2019 1 Anticancer Res 2 BJU Int 1 BMC Cancer 1 BMC Urol 1 Curr Treat Options Oncol 5 Eur Urol 2 Int J Radiat Oncol Biol Phys 2 Int J Urol 5 J Urol 1 N Engl J Med 1 PLoS One 1 Prog Urol 1 Prostate 1 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Anticancer Res

1. YAMAGUCHI N, Morizane S, Yumioka T, Iwamoto H, et al
   Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents.
   Anticancer Res. 2019;39:3879-3885.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

2. SCHELTEMA MJ, Chang JI, Stricker PD, van Leeuwen PJ, et al
   Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of
   BJU Int. 2019 Jul 9. doi: 10.1111/bju.14794.
   PubMed     Text format     Abstract available
   
   
3. BENARD A, Duroux T, Robert G
   Cost-utility analysis of focal HIFU versus active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state Model.
   BJU Int. 2019 Jul 12. doi: 10.1111/bju.14867.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

4. ZHU Y, Wang Y, Qian Z, Pan J, et al
   Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases.
   BMC Cancer. 2019;19:676.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

5. RONNINGAS U, Fransson P, Holm M, Wennman-Larsen A, et al
   Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden.
   BMC Urol. 2019;19:66.
   PubMed     Text format     Abstract available
   
   

   
   Curr Treat Options Oncol

6. WEINER AB, Nettey OS, Morgans AK
   Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
   Curr Treat Options Oncol. 2019;20:69.
   PubMed     Text format     Abstract available
   
   

   
   Eur Urol

7. PAL SK, Swami U, Agarwal N
   Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How.
   Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30519.
   PubMed     Text format    
   
   
8. VON EYBEN FE, Bauman G
   Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285-93.
   Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30516.
   PubMed     Text format    
   
   
9. DIRIX PR, Dal Pra A, Wiegel T
   Re: Gaetan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.016.
   Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30524.
   PubMed     Text format    
   
   
10. LOGOTHETIS CJ, Aparicio A, Koinis F, Corn PG, et al
    Prostate Cancer: Quo Vadis?
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30521.
    PubMed     Text format     Abstract available
    
    
11. DE BRUYCKER A, Fonteyne V, Ost P
    Re: Gaetan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.016.
    Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30523.
    PubMed     Text format    
    
    

    
    Int J Radiat Oncol Biol Phys

12. SALDI S, Bellavita R, Lancellotta V, Palumbo I, et al
    Acute Toxicity Profiles of Hypofractionated Adjuvant and Salvage Radiation Therapy After Radical Prostatectomy: Results of a Prospective Study.
    Int J Radiat Oncol Biol Phys. 2019;103:105-111.
    PubMed     Text format     Abstract available
    
    
13. BERLIN A, Murgic J, Hosni A, Pintilie M, et al
    Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.
    Int J Radiat Oncol Biol Phys. 2019;103:84-91.
    PubMed     Text format     Abstract available
    
    

    
    Int J Urol

14. ISHIKAWA H, Tsuji H, Murayama S, Sugimoto M, et al
    Particle therapy for prostate cancer: The past, present and future.
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14041.
    PubMed     Text format     Abstract available
    
    
15. FUKUHARA S
    Editorial Comment to Erectile function recovery at 12 months after radical prostatectomy for prostate cancer is not associated with overall survival.
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14064.
    PubMed     Text format    
    
    

    
    J Urol

16. FERNANDO H, Garcia C, Hossack T, Ahmadi N, et al
    Incidence, Predictive Factors and Preventive Measures for Inguinal Hernia following Robotic and Laparoscopic Radical Prostatectomy: A Systematic Review.
    J Urol. 2019;201:1072-1079.
    PubMed     Text format     Abstract available
    
    
17. SIEGEL C
    Re: PTEN Expression in Prostate Cancer: Relationship with Clinicopathologic Features and Multiparametric MRI Findings.
    J Urol. 2019 Jul 8:101097JU0000000000000428. doi: 10.1097/JU.0000000000000428.
    PubMed     Text format    
    
    
18. ATALA A
    Re: The Proteogenomic Landscape of Curable Prostate Cancer.
    J Urol. 2019 Jul 9:10109701JU000057698013730.
    PubMed     Text format    
    
    
19. TANEJA SS
    Re: Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jul 11:101097JU0000000000000443. doi: 10.1097/JU.0000000000000443.
    PubMed     Text format    
    
    
20. TANEJA SS
    Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    J Urol. 2019 Jul 11:10109701JU0000577260122781.
    PubMed     Text format    
    
    

    
    N Engl J Med

21. TANNOCK IF
    Improving Treatment for Advanced Prostate Cancer.
    N Engl J Med. 2019;381:176-177.
    PubMed     Text format    
    
    

    
    PLoS One

22. TOIVONEN J, Montoya Perez I, Movahedi P, Merisaari H, et al
    Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization.
    PLoS One. 2019;14:e0217702.
    PubMed     Text format     Abstract available
    
    

    
    Prog Urol

23. ROSE DITE MODESTINE J, Neuzillet Y, Herve JM, Bosset PO, et al
    [12-year history of radical surgery indications for the treatment of prostate cancer].
    Prog Urol. 2019 Jul 4. pii: S1166-7087(19)30157.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

24. ZHAO J, Zhang M, Liu J, Liu Z, et al
    AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Prostate. 2019 Jul 11. doi: 10.1002/pros.23875.
    PubMed     Text format     Abstract available
    
    

    
    Urology

25. PENA A, Qian Z, Lambrechts S, Cabri JN, et al
    Evaluation of implementation outcomes after initiation of a shared decision-making program for men with prostate cancer.
    Urology. 2019 Jul 9. pii: S0090-4295(19)30608.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: